Killackey Mary, Zhang Rubin, Sparks Kelly, Paramesh Anil, Slakey Douglas, Florman Sander
Division of Abdominal OrganTransplant, Tulane University Medical Center, New Orleans, LA, USA.
South Med J. 2010 Jun;103(6):532-40. doi: 10.1097/SMJ.0b013e3181ddd79a.
Obesity is a worldwide epidemic and public health crisis associated with severe comorbidity leading to end organ dysfunction and poorer transplant outcome. Large population studies show decreased patient and graft survival in obese kidney transplant patients. Despite the poorer outcomes, kidney transplant is considered because of the survival benefit as compared to the wait-listed dialysis patients. In liver transplantation, the benefit of transplant as compared to remaining on the list is obvious because there is no viable liver dialysis at this time.Obesity in potential organ donors impacts both medical and surgical issues. Obesity-related kidney disease affects both the remaining and transplanted kidney. Pancreas donor organs are associated with decreased early graft survival. Liver donor organs with significant steatosis lead to an increased risk for delayed function or nonfunction of the organ.Immunosuppressive drugs with variable lipophilicity and altered volume of distribution can greatly affect the therapeutic usefulness of these drugs.Transplant candidates benefit from a multidisciplinary team approach to their care. As the epidemic progresses and less invasive treatments for metabolic surgery evolve, we are likely to see more patients lose weight before transplant as we continue to strive for improved outcomes.
肥胖是一种全球性的流行病和公共卫生危机,与严重的合并症相关,可导致终末器官功能障碍和移植结果较差。大型人群研究表明,肥胖肾移植患者的患者和移植物存活率降低。尽管结果较差,但与等待透析的患者相比,肾移植因具有生存益处而被考虑。在肝移植中,与继续等待相比,移植的益处很明显,因为目前没有可行的肝透析方法。潜在器官供体的肥胖会影响医学和外科问题。肥胖相关肾病会影响剩余的肾脏和移植的肾脏。胰腺供体器官与早期移植物存活率降低有关。存在明显脂肪变性的肝脏供体器官会增加器官功能延迟或无功能的风险。具有不同亲脂性和分布容积改变的免疫抑制药物会极大地影响这些药物的治疗效果。移植候选者受益于多学科团队的护理方法。随着这一流行病的发展以及代谢手术的微创治疗方法不断演进,随着我们继续努力改善结果,我们可能会看到更多患者在移植前体重减轻。